Drugs / Pexa-Vec
Pexa-Vec
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02977156 | Jan 2017 → Apr 2022 | metastatic neoplasm | Centre Leon Berard | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04849260 | Aug 2021 → May 2022 | metastatic melanoma | Lee's Pharmaceutical Limited | Unknown | No outcome recorded |
| Phase 1/2 | NCT03206073 | Dec 2017 → Sep 2020 | colorectal adenocarcinoma, refractory malignant neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
Press releases naming this drug 7 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PexaVec | “BACKGROUND: Oncolytic immunotherapy represents a unique therapeutic platform for the treatment of cancer. Here, we evaluated the safety and efficacy of the combination of...” PMID 36754451 ↗ Feb 2023 |
| Known as | JX-594 | “Pexa-Vec (JX-594) is a thymidine kinase gene-inactivated oncolytic vaccinia virus engineered for the expression of transgenes encoding human granulocyte- macrophage...” NCT03206073 ↗ |
| Known as | Pexa-Vec, INN pexastimogene devacirepvec | “Pexa-Vec, INN pexastimogene devacirepvec” NCT03206073 ↗ |
| Known as | Pexastimogene Devacirepvec | “Pexastimogene Devacirepvec (Pexa-Vec) is one of the new vaccinia oncolytic viruses genetically modified to express GM-CSF.” NCT02977156 ↗ |
| Modality | Other / unclassified | “Oncolytic live replicating virus, Recombinant vaccinia virus GM-GCF” NCT02977156 ↗ |
| Route | Other | “administered by Intra-tumoral injection” NCT02977156 ↗ |